Download PDF
Deutsche Zeitschrift für Onkologie 2019; 51(04): 158-164
DOI: 10.1055/a-1030-3015
Forschung
© Georg Thieme Verlag KG Stuttgart · New York

Eine gesunde Darmmikrobiota unterstützt die Barriere-Funktion der Mukosa

A Healthy Gut Microbiota Enhances the Barrier Function of the Mucosa
Angelika Hecht
1   SymbioPharm GmbH, Herborn
,
Elke Jaspers
2   mikroLogos GmbH, Duisburg
› Author Affiliations
Further Information

Publication History

Publication Date:
12 December 2019 (online)

    Permissions and Reprints

ZUSAMMENFASSUNG

Die Darmschleimhaut hat gegensätzlich erscheinende Aufgaben: Einerseits dient sie der Resorption von Nährstoffen, andererseits bildet sie gleichzeitig eine Barriere zwischen der Außenwelt und dem Körperinneren. Zur Dichtigkeit der Mukosa tragen eine unversehrte Mukusschicht auf dem Epithel, gut ernährte Epithelzellen mit intakten Tight Junctions und insbesondere eine gesunde Darmmikrobiota bei. Ist die Barriere geschädigt, steigt das Risiko für eine Silent Inflammation, die den ganzen Körper betrifft und für zahlreiche chronische Erkrankungen verantwortlich ist.

ABSTRACT

The gut mucosa has different functions, which, at first glance, seem to be contradictory: On the one hand, the intestinal mucosa resorbs nutrients, but on the other hand it also forms a barrier between the outside and inside of the body. Several factors contribute to the correct mucosal function: An intact mucus layer on top of the epithelium, a well-fed epithelial cell layer including their tight junctions, and especially a healthy gut microbiota. A damaged gut barrier increases the risk for acquiring a silent inflammation, which is responsible for a wide range of chronic diseases.

Schlüsselwörter

Darmmikrobiota - Mukosa - Darmbarriere - Tight Junctions - Leaky Gut - Silent Inflammation

Key words

Gut microbiota - mucosa - intestinal barrier - tight junctions - leaky gut - silent inflammation
 

  • Literatur

  • 1 Jungersen M. et al. The science behind the probiotic strain Bifidobacterium animalis subsp. lactis BB-12®. Microorganisms 2014; 2: 92-110. doi:10.3390/microorganisms2020092
    CrossrefPubMedGoogle Scholar
  • 2 Zschüttig A. et al. Identification and characterization of Microcin S, a new antibacterial peptide produced by probiotic Escherichia coli G3/10. PLoS One 2012; 7: e33351. doi:10.1371/journal.pone.0033351
    CrossrefPubMedGoogle Scholar
  • 3 Louis P, Flint HJ. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett 2009; 294: 1-8. doi:10.1111/j.1574-6968.2009.01514.x
    CrossrefPubMedGoogle Scholar
  • 4 Bischoff SC. Hrsg Probiotika, Präbiotika, Symbiotika. Stuttgart: Thieme; 2009. ISBN: 9783131551511
    Google Scholar
  • 5 Gonçalves P, Martel F. Butyrate and colorectal cancer: the role of butyrate transport. Curr Drug Metab 2013; 14: 994-1008
    CrossrefPubMedGoogle Scholar
  • 6 Ferreira-Halder CV. et al. Action and function of Faecalibacterium prausnitzii in health and disease. Best Pract Res Clin Gastroenterol 2017; 31: 643-648. doi:10.1016/j.bpg.2017.09.011
    CrossrefPubMedGoogle Scholar
  • 7 Duncan SH, Holtrop G, Lobley GE. Contribution of acetate to butyrate formation by human faecal bacteria. Br J Nutr 2004; 91: 915-923
    CrossrefPubMedGoogle Scholar
  • 8 Ze X. et al. Rumincoccus bromii is a keystone species for the degradation of resistant starch in the human colon. ISME J 2012; 6: 1535-1543. doi:10.1038/ismej.2012.4
    CrossrefPubMedGoogle Scholar
  • 9 Keenan MJ. et al. Role of resistant starch in improving gut health, adiposity, and insulin resistance. Adv Nutr 2015; 6: 198-205. doi:10.3945/an.114.007419
    CrossrefPubMedGoogle Scholar
  • 10 Rhodes JM. Mucins and inflammatory bowel disease. Q J Med 1997; 90: 79-82. doi:10.1093/qjmed/90.2.79
    PubMedGoogle Scholar
  • 11 Hansson GG. Role of mucus layers in gut infection and inflammation. Curr Opin Microbiol 2012; 15: 57-62 doi:10.1016/j.mib.2011.11.002
    CrossrefPubMedGoogle Scholar
  • 12 Vaishnava S. et al. The antibacterial lectin RegIIIgamma promotes the spatial segregation of microbiota and host in the intestine. Science 2011; 334 (6053) 255-258. doi:10.1126/science.1209791
    CrossrefPubMedGoogle Scholar
  • 13 Heyn G. Sensible Festung gegen Angreifer. Pharmazeutische Zeitung online 2006; Ausgabe 5. https://www.pharmazeutische-zeitung.de/ausgabe-052006/sensible-festung-gegen-angreifer/
    PubMed
  • 14 Cani PD, de Vos WM. Next-generation beneficial microbes: the case of Akkermansia muciniphila. Front Microbiol 2017; 8: 1765 doi:10.3389/fmicb.2017.01765
    CrossrefPubMedGoogle Scholar
  • 15 Ottman N. et al. Action and function of Akkermansia muciniphila in microbiome ecology, health and disease. Best Pract Res Clin Gastroenterol 2017; 31: 637-642. doi:10.1016/j.bpg.2017.10.001
    CrossrefPubMedGoogle Scholar
  • 16 König J. et al. Human intestinal barrier function in health and disease. Clin Transl Gastroenterol 2016; 7: e196. doi:10.1038/ctg.2016.54
    CrossrefPubMedGoogle Scholar
  • 17 Yu Q. et al. Lactobacillus protects the integrity of intestinal epithelial barrier damaged by pathogenic bacteria. Front Cell Infect Microbiol 2015; 5: 26 doi:10.3389/fcimb.2015.00026
    CrossrefPubMedGoogle Scholar
  • 18 Najarian A, Sharif S, Griffiths MW. Evaluation of protective effect of Lactobacillus acidophilus La-5 on toxicity and colonization of Clostridium difficile in human epithelial cells in vitro. Anaerobe 2019; 55: 142-151. doi:10.1016/j.anaerobe.2018.12.004
    CrossrefPubMedGoogle Scholar
  • 19 Rao RK, Samak G. Protection and restitution of gut barrier by probiotics: nutritional and clinical implications. Curr Nutr Food Sci 2013; 9: 99-107
    CrossrefPubMedGoogle Scholar
  • 20 Chassaing B. et al. Dietary emulsifiers directly alter human microbiota composition and gene expression ex vivo potentiating intestinal inflammation. Gut 2017; 66: 1414-1427 doi:10.1136/gutjnl-2016-313099
    CrossrefPubMedGoogle Scholar
  • 21 Lerner A, Matthias T. Changes in intestinal tight junction permeability associated with industrial food additives explain the rising incidence of autoimmune disease. Autoimmun Rev 2015; 14: 479-489. doi:10.1016/j.autrev.2015.01.009
    CrossrefPubMedGoogle Scholar
  • 22 Lambertz J. et al. Fructose: a dietary sugar in crosstalk with microbiota contributing to the development and progression of non-alcoholic liver disease. Front Immunol 2017; 8: 1159 doi:10.3389/fimmu.2017.01159
    CrossrefPubMedGoogle Scholar
  • 23 Ostermann AL. et al. Intestinal insulin/IGF1 signalling through FoxO1 regulates epithelial integrity and susceptibility to colon cancer. Nature Metabolism 2019; 1: 371-389 doi:10.1038/s42255-019-0037-8
    CrossrefPubMedGoogle Scholar
  • 24 Cani PD. et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56: 1761-1772
    CrossrefPubMedGoogle Scholar
  • 25 Kim JJ, Sears DD. TLR4 and insulin resistance. Gastroenterol Res Pract 2010; 2010 pii 212563. doi:10.1155/2010/212563
    PubMedGoogle Scholar
  • 26 Liang H. et al. Effect of lipopolysaccharide on inflammation and insulin action in human muscle. PLoS One 2013; 8: e63983. doi:10.1371/journal.pone.0063983
    CrossrefPubMedGoogle Scholar
  • 27 Pussinen PJ. et al. Endotoxemia is associated with an increased risk of incident diabetes. Diabetes Care 2011; 34: 392-397 doi:10.2337/dc10-1676
    CrossrefPubMedGoogle Scholar
  • 28 Jayashree B. et al. Increased circulatory levels of lipopolysaccharide (LPS) and zonulin signify novel biomarkers of proinflammation in patients with type 2 diabetes. Mol Cell Biochem 2014; 388: 203-210. doi:10.1007/s11010-013-1911-4
    CrossrefPubMedGoogle Scholar
  • 29 Sturgeon C, Fasano A. Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases. Tissue Barriers 2016; 4: e1251384
    CrossrefPubMedGoogle Scholar
  • 30 Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev 2011; 91: 151-175 doi:10.1152/physrev.00003.2008
    CrossrefPubMedGoogle Scholar
  • 31 Stevens BR. et al. Increased human intestinal barrier permeability plasma biomarkers zonulin and FABP2 correlated with plasma LPS and altered gut microbiome in anxiety or depression. Gut 2018; 67: 1555-1557. doi:10.1136/gutjnl-2017-314759
    PubMedGoogle Scholar
  • 32 Schwiertz A. et al. Fecal markers of intestinal inflammation and intestinal permeability are elevated in Parkinson̓s disease. Parkinsonism Relat Disord 2018; 50: 104
    CrossrefPubMedGoogle Scholar
  • 33 Esnafoglu E, Cırrık S, Ayyıldız SN. et al. Increased serum zonulin levels as an intestinal permeability marker in autistic subjects. J Pediatr 2017; 188: 240-244 doi:10.1016/j.jpeds.2017.04.004
    CrossrefPubMedGoogle Scholar
  • 34 Macpherson AJ, Uhr T. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science 2004; 303: 1662-1665
    CrossrefPubMedGoogle Scholar
  • 35 McGhee JR, Fujihashi K. Inside the mucosal immune system. PLOS One 2012; 10: e1001397
    PubMedGoogle Scholar
  • 36 Siddiqui I, Majid H, Abid S. Update on clinical and research application of fecal biomarkers for gastrointestinal diseases. World J Gastrointest Pharmacol Ther 2017; 8: 39-46. doi:10.4292/wjgpt.v8.i1.39
    PubMedGoogle Scholar
  • 37 Rusch V, Zimmermann K. Microbial therapy with Enterococcus faecalis and Escherichia coli: Experimental and clinical data. In Fuller R. et al. ed Probiotics: Prospects of use in opportunistic infections. Old Herborn University: Institute for Microbiology and Biochemistry; 1995
    Google Scholar
  • 38 Habermann W. et al. Einfluss eines bakteriellen Immunstimulans (humane Enterococcus faecalis-Bakterien) auf die Rezidivhäufigkeit bei Patienten mit chronischer Bronchitis. Arzneim Forsch 2001; 51: 931-937
    PubMedGoogle Scholar
  • 39 Habermann W. et al. Verminderung der Rezidivhäufigkeit bei Patienten mit chronisch rezidivierender hypertrophischer Sinusitis unter Behandlung mit einem bakteriellen Immunstimulans (Enterococcus faecalis-Bakterien humaner Herkunft). Arzneim Forsch 2002; 52: 622-627
    PubMedGoogle Scholar
  • 40 Peters A. et al. Metabolites of lactic acid bacteria present in fermented foods are highly potent agonists of human hydroxycarboxylic acid receptor 3. PLoS Genet 2019; 15 (5) e1008145 doi:10.1371/journal.pgen.1008145
    CrossrefPubMedGoogle Scholar
  • 41 Alsheridah N, Akhtar S. Diet, obesity and colorectal carcinoma risk: results from a national cancer registry-based middle-eastern study. BMC Cancer 2018; 18 (1): 1227
    CrossrefPubMedGoogle Scholar